Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by mdjbrownon Mar 26, 2024 11:00am
114 Views
Post# 35952964

Increased exposure through product in Germany wont hurt

Increased exposure through product in Germany wont hurtMedipharm in the long run.  Almost tripling product approvals is a good start to 2024

"Thus far in 2024, MediPharm has increased the German product approvals under the Beacon Medical brand from 5 to 14"


Lets see if Medipharm numbers increase substantially from last years financial reporting at this time

Most of MediPharm’s sales in the January-March quarter were in Canada.

"By jurisdiction, the company’s revenue was:

  • CA$3.9 million in Canada.
  • CA$51,000 in Australia.
  • CA$1.2 million in Germany.
  • CA$575,000 in other, unspecified places.

MediPharm’s sales in the Canadian adult-use and wellness sector were C$3.5 million in the first quarter, up from CA$2.5 million in the same period last year.

International medical cannabis sales amounted to CA$1.8 million, up from CA$1.3 million in the first quarter last year."

<< Previous
Bullboard Posts
Next >>